NIG 1 1899 M STO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. SERIAL NO. 2026-4269US1 09/529,206

APPLICANT

WANG ET AL.

(Use several sheets if necessary)

ORMATION DISCLOSURE CITATION

FILING DATE GROUP ART UNIT June 13, 2000 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
:						

FOREIGN PATENT DOCUMENTS

		DATE	COUNTRY		SUBCLASS	TRANSLATION	
	DOCUMENT NUMBER			CLASS		YES	NO
NAO	WO 94/03205	2/17/94	WIPO				
	WO 97/29195	8/4/97	WIPO				
	WO 98/14464	4/9/98	WIPO				
	WO 98 32855	6/30/98	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

NA	Chen YT., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94:1914 (1997).					
,	Jager, E., et al. Simultaneous humoral and cellular immu8ne response against cancer-testis antigen NY-ESO-1: definition of human histocompativility leukocyte antigen (HLA)-A2-binding peptide eptiopes. J. Exp. Med. 187:265 (1998).					
	Parkhurst, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp 100 modified at HLA-A0201 binding residues. J. Immunol. 157:2539 (1996).					
	Wang, R., et al., A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different from different open reading frames. J. Immunol. 161:3596 (1998).					
	Falk et al. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules Immunogenetics, Vol. 40: 238-241 (1994).					

EORX PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-4269US1	SERIAL NO. 09/529,206
wou in			APPLICANT	
INEO	RMAT	ION DISCLOSURE CITATION	WANG ET AL.	
A BELL	(Use s	several sheets if necessary)	FILING DATE June 13, 2000	GROUP ART UNIT 1643
MAD		Kawakami, Y et al. Identification of Melanoma Antigen Recognized by th lymphocytes. J. Exp. Med., Vol. 180	e Majority of HLA-A2-res	
		Wang, R-F et al. Identification of a g HLA-A31-restricted tumor-infiltratin		
		Rammensee, H.G. et al. MHC ligand 178 (1995).	and peptide motifs: first	listing, Immunogenetics, Vol. 41:
		Wang, R-F, et al. Utilization of an A Generating a Novel Human Cancer A		
		Wang and Rosenberg, Human tumor cancer therapy, J. Leukocyte Biology	• •	ymphocytes: implications for
		Wang, R-F et al., Identification of TR lymphocytes. J. Exp. Med., Vol. 184		ntigen Recognized by cytotoxic T
\downarrow		Kawakami Y et al. Identification of t Advances in Oncology, 1996, eds. V. Publishers, Philadelphia, pp. 3-21		
	` ^	delimon 1	DATE CONSIDERED	9-15-004

M&F REV. 06/29/95

applicant.